SMS Pharmaceuticals share news, announcements and annual reports
NSE: SMSPHARMABSE: 532815Pharmaceuticals & BiotechnologySmall Cap
SMS Pharmaceuticals Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2007
Last close ₹511.35up ₹25.55 (5.26%)BSE ₹511.75
Share price at the NSE close on 30 Oct 2026. Previous close ₹485.80.
30 Oct: open ₹499.70, high ₹525.00, low ₹482.20
52-week range of traded prices to 30 Oct 2026
₹270.10Low, 24 Nov 2025₹525.00High, 30 Oct 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹4,789 Cr920th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 46.63
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.09
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.08%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 14.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 11.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.46
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 43,04,85521.5% delivered
SMS Pharmaceuticals board meetings
148 filed, newest first. Page 2 of 3.
Nov 2019
Aug 2019
12 Aug · Board meeting
5 Aug · Board meeting
May 2019
27 May · Board meeting
18 May · Board meeting
Feb 2019
14 Feb · Board meeting
6 Feb · Board meeting
Nov 2018
Jul 2018
21 Jul · Board meeting
May 2018
26 May · Board meeting
Feb 2018
8 Feb · Board meeting
Jan 2018
Dec 2017
13 Dec · Board meeting
Sep 2017
27 Sep · Board meeting
13 Sep · Board meeting
Aug 2017
11 Aug · Board meeting
May 2017
Feb 2017
Oct 2016
Aug 2016
11 Aug · Board meeting
May 2016
Mar 2016
Feb 2016
12 Feb · Board meeting
Out come of the Board Meeting
Jan 2016
Dec 2015
Nov 2015
Oct 2015
9 Oct · Board meeting
Aug 2015
8 Aug · Board meeting
Jul 2015
Jun 2015
May 2015
Feb 2015
6 Feb · Board meeting
Board of Directors of the Company at their meeting held on February 06, 2015 has appointed an Independent Committee to explore the possibilities of Demerger of Non-FDA Manufacturing Units of the Company and submit a detailed report to the Board for consideration.
Jan 2015
27 Jan · Board meeting
Interalia, to consider the Un-audited Financial Results of the Company for the Quarter ended December 31, 2014 with limited review report.
Nov 2014
5 Nov · Board meeting
Inter alia, to consider the Un-audited Financial Results of the Company for the quarter ended September 30, 2014 with limited review report.
Aug 2014
26 Aug · Board meeting
Board has taken the following decisions in its meeting held on August 26, 2014: 1. Approved the Directors' Report. 2. Approved and recommended for Re-appointment of M/s. Rambabu & Co., Chartered Accounts as Sole Auditors of the Company for a period of 1 (one) year. 3. Approved Mr. C. Sudhir Babu, Practicing Company Secretary as Scrutinizer for conduct of e-voting process.